



As of February 2023

# RAISE Healthcare Initiative

---

Emerging biotechnologies are being developed to provide hope and healing for our neighbors who are vulnerable. We recognize that investors delight in the value new treatments can create for communities, but so often we hear stories about patients who are struggling with access and affordability.

**Eventide believes that industry and investors are well-positioned to address these challenges.**

We have the opportunity to leverage the power of purposeful investing to remove impediments to treatment—so that the healthcare system can truly promote health and patients can turn their imaginations to holistic wellbeing. As an extension of our Business 360<sup>®</sup> framework, our team is launching a new industry-specific initiative to motivate biotech companies towards sustainable strategy.



“Our vision is  
a world where  
*medical innovation*  
is encouraged,  
where *patient need*  
is met with access,  
and *value is*  
*justly rewarded.*”



Eventide believes that industry and investors are best positioned to address drug pricing challenges.

---

## GUIDING PRINCIPLES:

- **Transformational Medical Therapies**

We believe that treatments ought to meaningfully transform the patient's life expectancy and/or quality of life. We embrace companies pursuing treatments that significantly improve upon current therapies: either by way of reducing side effects/adverse events, increasing expected life years, or bettering quality of life; additionally, we seek treatments that will impact spending, driving down long-term systemic costs associated with a respective condition.
- **Commitment to Bioethical Principles and Practices**

We affirm organizational values, culture, and leadership with a commitment to bioethical alignment and the principles outlined by the Belmont Report in animal studies, clinical trials, and service to the patient population. We believe that transparency is imperative in continuing to drive innovation. We encourage companies to avoid misleading data presentation and other forms of skew designed to promote the company at the expense of the highest ethical standards.
- **Ethical and Effective Corporate Governance**

In accordance with Eventide's Business 360<sup>®</sup> diligence criteria, companies must promote ethical and effective corporate governance.
- **Sensible and Sustainable Pricing**

We recognize that a treatment's price ought to be sensible and sustainable, simultaneously respecting the healthcare ecosystem and allowing for innovative companies, their researchers, and their supporters to be remunerated fairly for their investment. We engage with companies to encourage responsible stewardship of capital to ensure that inappropriate costs will not be passed on to patients. We advocate for expanded cost effectiveness analyses to encourage ethical exploration within a range of prices.
- **Principled Corporate Strategy**

We hold that once a treatment is available to patients, companies should engage in principled corporate strategy with attention to avoiding Pharmacy Benefit Manager kickbacks, low-value reformulations, pay-for-delay, etc. We believe the company ought to look to "genericize" their product after a specified period of time.
- **Integrity-Driven Education**

We note that within the healthcare ecosystem, companies play a vital role in educating clinicians, healthcare providers, and patients about emerging therapies. We believe that companies should minimize inherent conflict-of-interest and promote marketing practices that are forthright and evidence-based.

When patients feel the financial strain of a treatment that does not reflect its value, society suffers and condemns the business.

## STAKEHOLDER ENGAGEMENT – WHAT WE DO:


**Current Areas of Impact:** Biotech and Specialty Pharma Companies

- Hold our portfolio companies to industry-specific RAISE guiding principles, in research and development, governance, pricing, and corporate strategy.
- Engage our portfolio companies through our Business 360® framework, offering ongoing evaluation and recommendations with respect to RAISE guiding principles.
- Partner with portfolio companies to ensure just value of a treatment and appropriate capital allocation.
- Develop resources and tools for portfolio companies to operationalize an ethical, patient-centric culture.
- Identify strategic investments to reduce value extraction in the healthcare system.

---

## OUR TIMELINE:

When it comes to drug pricing, there is no “quick fix” to the challenges stakeholders across the healthcare ecosystem face. By leveraging the Business 360® “Engage” approach, we hope to create long-term impact through collaboration with our portfolio partners and co-investors. Through our historic efforts in stakeholder and shareholder engagement, we’ve identified three strategic phases for the RAISE Healthcare initiative:



---

**NOTES**

1. Office for Human Research Protections (OHRP). "Read the Belmont Report." HHS.gov, <https://www.hhs.gov/ohrp/regulations-and-policy/belmont-report/read-the-belmont-report/index.html>.
- 

---

**DISCLAIMER**

The RAISE (Restoration, Access, Innovation, Stewardship and Ethics) Healthcare Initiative is a part of Eventide's Business 360<sup>®</sup> framework, to help promote sensible corporate strategy and pricing throughout the healthcare industry. There is no guarantee that Eventide's RAISE Healthcare Initiative will achieve its intended results. Any reference to Eventide's Business 360<sup>®</sup> approach is provided for illustrative purposes only and indicates a general framework of guiding principles that inform Eventide's overall research process.

Ethical values screening criteria could cause an investment to underperform similar investments that do not have such screening criteria. This could be due to ethically acceptable companies falling out of favor with investors or failing to perform as well as companies that do not meet the investment's ethical screening guidelines. To supplement its efforts in ethical investing, the Adviser is specifically engaged in the promotion of sensible corporate strategy and pricing in the healthcare industry. The Adviser believes these activities will help promote ethical and effective corporate governance and long term strategy for healthcare companies, and potentially create a positive effect on the healthcare industry, and for investors. There is no guarantee the Adviser's activities would achieve their intended results. There is a risk that the Adviser's activities in this regard could limit the investment universe and reduce the amount of profits that could be realized by affected companies, limiting investment returns. Furthermore, the US government or any agency thereof, may enact rules or legislation that, directly or indirectly, materially impacts the Adviser's activities in this regard, or materially affects the value of the healthcare companies.